NBY - יחס מחיר להכנסות NovaBay Pharmaceuticals Inc.

The historical P/S on the current GURU.Markets platform chart recorded a value of 18.50. NovaBay Pharmaceuticals (NBY) sales dynamics are complicated by severe pricing pressure in the over-the-counter segment. However, the company is developing niche potential by creating safe Avenova antimicrobial formulas. Automated assembly lines of contract partners, operating on a strict schedule, ensure the stability of product output.

The P/S ratio compares the market capitalization of NovaBay Pharmaceuticals (NBY) to its annual sales volume, determining the cost of one dollar of revenue. By analyzing the price-to-sales metric, an investor assesses the extent of the premium paid for the business relative to its actual cash flows. A decline in this metric may signal that the asset is undervalued. This is critical for NovaBay Pharmaceuticals (NBY), as intense generic pressure and marketing expenses limit margin growth.